JP2022511453A5 - - Google Patents
Info
- Publication number
- JP2022511453A5 JP2022511453A5 JP2021530800A JP2021530800A JP2022511453A5 JP 2022511453 A5 JP2022511453 A5 JP 2022511453A5 JP 2021530800 A JP2021530800 A JP 2021530800A JP 2021530800 A JP2021530800 A JP 2021530800A JP 2022511453 A5 JP2022511453 A5 JP 2022511453A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- isolated nucleic
- injection
- vector
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024128634A JP2024177670A (ja) | 2018-11-28 | 2024-08-05 | 神経変性疾患のための遺伝子治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862772230P | 2018-11-28 | 2018-11-28 | |
| US62/772,230 | 2018-11-28 | ||
| PCT/US2019/063289 WO2020112802A1 (en) | 2018-11-28 | 2019-11-26 | Gene therapies for neurodegenerative disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128634A Division JP2024177670A (ja) | 2018-11-28 | 2024-08-05 | 神経変性疾患のための遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511453A JP2022511453A (ja) | 2022-01-31 |
| JP2022511453A5 true JP2022511453A5 (cg-RX-API-DMAC7.html) | 2022-11-21 |
| JP7616995B2 JP7616995B2 (ja) | 2025-01-17 |
Family
ID=70852200
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530800A Active JP7616995B2 (ja) | 2018-11-28 | 2019-11-26 | 神経変性疾患のための遺伝子治療 |
| JP2024128634A Withdrawn JP2024177670A (ja) | 2018-11-28 | 2024-08-05 | 神経変性疾患のための遺伝子治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024128634A Withdrawn JP2024177670A (ja) | 2018-11-28 | 2024-08-05 | 神経変性疾患のための遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220010001A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3887396A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7616995B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210096168A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113557243A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019388975A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021010234A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3121211A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283496B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021006253A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020112802A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| JP2023500793A (ja) * | 2019-10-16 | 2023-01-11 | コーネル・ユニバーシティー | アルツハイマー病に対する遺伝子治療方法 |
| KR20220107243A (ko) | 2019-11-25 | 2022-08-02 | 코넬 유니버시티 | Apoe 유전자 요법 |
| AU2021364596A1 (en) * | 2020-10-22 | 2023-06-08 | Duke University | Compositions and methods relating to alzheimer's disease |
| KR20230112672A (ko) * | 2020-11-25 | 2023-07-27 | 프리베일 테라퓨틱스, 인크. | 신경변성 질환을 위한 유전자 요법 |
| WO2023078883A1 (en) * | 2021-11-03 | 2023-05-11 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating apolipoprotein e4 expression |
| AR131035A1 (es) * | 2022-11-11 | 2025-02-12 | Lilly Co Eli | Ácidos nucleicos sintéticos que incluyen constructos promotores dirigidos a astrocitos y métodos de uso de los mismos |
| CN119220609B (zh) * | 2024-09-27 | 2025-09-12 | 科辉智药(深圳)新药研究中心有限公司 | 一种共表达TRIM11和ApoE2的核酸序列构建体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2142300C (en) * | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| ATE387459T1 (de) * | 2000-04-06 | 2008-03-15 | Kos Pharma Inc | Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie |
| US20050019927A1 (en) * | 2003-07-13 | 2005-01-27 | Markus Hildinger | DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
| US8435539B2 (en) * | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| EP1991252A2 (en) * | 2006-02-21 | 2008-11-19 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
| US20150183850A1 (en) * | 2012-05-18 | 2015-07-02 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
| WO2013181618A2 (en) * | 2012-05-31 | 2013-12-05 | The Trustees Of Columbia University In The City Of New York | Methods to treat alzheimer's disease using apoe inhibitors |
| WO2014028461A2 (en) * | 2012-08-13 | 2014-02-20 | The Rockefeller University | Treatment and diagnosis of melanoma |
| ES2874704T3 (es) * | 2013-11-20 | 2021-11-05 | Univ Iowa Res Found | Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE |
| WO2015153760A2 (en) * | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
| EP3191578B1 (en) * | 2014-09-12 | 2020-11-04 | Whitehead Institute for Biomedical Research | Cells expressing apolipoprotein e and uses thereof |
| WO2018045347A1 (en) * | 2016-09-02 | 2018-03-08 | Spark Therapeutics, Inc. | Methods and vectors for treating cns disorders |
| BR112019023303A2 (pt) * | 2017-05-11 | 2020-06-16 | The Trustees Of The University Of Pennsylvania | Terapia de gene para lipofuscinoses ceroides neuronais |
| JP2023500793A (ja) * | 2019-10-16 | 2023-01-11 | コーネル・ユニバーシティー | アルツハイマー病に対する遺伝子治療方法 |
-
2019
- 2019-11-26 CA CA3121211A patent/CA3121211A1/en active Pending
- 2019-11-26 JP JP2021530800A patent/JP7616995B2/ja active Active
- 2019-11-26 MX MX2021006253A patent/MX2021006253A/es unknown
- 2019-11-26 BR BR112021010234-5A patent/BR112021010234A2/pt not_active Application Discontinuation
- 2019-11-26 KR KR1020217019516A patent/KR20210096168A/ko not_active Ceased
- 2019-11-26 EP EP19889757.1A patent/EP3887396A4/en active Pending
- 2019-11-26 CN CN201980086952.0A patent/CN113557243A/zh active Pending
- 2019-11-26 US US17/297,492 patent/US20220010001A1/en not_active Abandoned
- 2019-11-26 AU AU2019388975A patent/AU2019388975A1/en not_active Abandoned
- 2019-11-26 IL IL283496A patent/IL283496B2/en unknown
- 2019-11-26 WO PCT/US2019/063289 patent/WO2020112802A1/en not_active Ceased
-
2024
- 2024-08-05 JP JP2024128634A patent/JP2024177670A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331409A1 (en) | Factor ix gene therapy | |
| CA3121211A1 (en) | Gene therapies for neurodegenerative disease | |
| JP2022531861A5 (cg-RX-API-DMAC7.html) | ||
| JP2022060228A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537544A5 (cg-RX-API-DMAC7.html) | ||
| JP2023503637A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537543A5 (cg-RX-API-DMAC7.html) | ||
| JP2022549380A5 (cg-RX-API-DMAC7.html) | ||
| TW202005978A (zh) | 新穎肝靶向腺相關病毒載體 | |
| JP2021500049A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537542A5 (cg-RX-API-DMAC7.html) | ||
| JP2023537625A5 (cg-RX-API-DMAC7.html) | ||
| IL278213B1 (en) | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) | |
| JP2022530824A5 (cg-RX-API-DMAC7.html) | ||
| JP2023537980A5 (cg-RX-API-DMAC7.html) | ||
| CA2972038C (en) | Adeno-associated virus vectors encoding modified g6pc and uses thereof | |
| US20240318199A1 (en) | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders | |
| WO2023060269A4 (en) | Recombinant adeno-associated viruses for targeted delivery | |
| JP2022530833A5 (cg-RX-API-DMAC7.html) | ||
| JP2021507687A5 (cg-RX-API-DMAC7.html) | ||
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| WO2021216975A1 (en) | Aav native-neuro platform and use for neuronal disease gene therapy | |
| JP2022530095A5 (cg-RX-API-DMAC7.html) | ||
| FI3953377T3 (fi) | Geeniterapioita lysosomaalisiin sairauksiin | |
| IL300294A (en) | Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences |